Viewing Study NCT02847559


Ignite Creation Date: 2025-12-24 @ 3:03 PM
Ignite Modification Date: 2026-02-20 @ 6:45 PM
Study NCT ID: NCT02847559
Status: RECRUITING
Last Update Posted: 2025-06-27
First Post: 2016-07-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Sponsor: Northwestern University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anaplastic (Malignant) Meningioma View
None Atypical Meningioma View
None Grade II Meningioma View
None Grade III Meningioma View
None Recurrent Meningioma View
None Supratentorial Meningioma View
Keywords: